ticlopidine has been researched along with Arterial Occlusive Diseases in 94 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ticlopidine is increasingly used in the secondary prophylaxis in patients with arterial occlusive diseases." | 7.70 | Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C. ( Ehringer, H; Minar, E; Parschalk, B; Redlich, K, 1999) |
| "Ferric chloride has been widely used to induce arterial thrombosis in a variety of species." | 5.33 | An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. ( Wang, X; Xu, L, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Clopidogrel reduces arterial thrombus cohesion by an effect that correlates with inhibition of ADP-induced platelet aggregation." | 5.32 | Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. ( Bal dit Sollier, C; Berge, N; Bergmann, JF; Drouet, L; Mahé, I; Simoneau, G, 2003) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 5.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| "Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis." | 5.24 | The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017) |
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "Ticlopidine is increasingly used in the secondary prophylaxis in patients with arterial occlusive diseases." | 3.70 | Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C. ( Ehringer, H; Minar, E; Parschalk, B; Redlich, K, 1999) |
| "Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease." | 3.70 | Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999) |
| "Combination antiplatelet agents, particularly aspirin and ticlopidine, have found increased use in the prevention of arterial thrombosis." | 3.70 | A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. ( Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G, 2000) |
| "Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells." | 2.80 | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results. ( Chen, YX; Gu, YQ; Hu, HJ; Li, XQ; Liu, CW; Song, XJ; Tian, HY; Wang, WD; Zhao, JC, 2015) |
| "Aspirin has been shown to be effective in reducing the associated risk of myocardial infarction and stroke." | 2.40 | Management of peripheral arterial disease. ( Hilleman, DE, 1998) |
| "Arterial thrombosis was induced by insertion of a silk thread (thrombogenic substrate) into an extracorporeal shunt." | 1.36 | Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. ( Calmettes, Y; Le Grand, B; Leparq-Panissié, A; Létienne, R; Nadal-Wollbold, F; Perez, M, 2010) |
| "Ferric chloride has been widely used to induce arterial thrombosis in a variety of species." | 1.33 | An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. ( Wang, X; Xu, L, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "Clopidogrel reduces arterial thrombus cohesion by an effect that correlates with inhibition of ADP-induced platelet aggregation." | 1.32 | Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens. ( Bal dit Sollier, C; Berge, N; Bergmann, JF; Drouet, L; Mahé, I; Simoneau, G, 2003) |
| "Most patients with PAD die of either heart attacks or strokes and they die of the former conditions far earlier than controls." | 1.32 | [Antiplatelet therapy in patients with peripheral arterial disease (PAD)]. ( Diehm, C; Huber, R; Lawall, H, 2004) |
| "No or only a mild restenosis developed in 27 patients." | 1.32 | Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results. ( Butz, B; Feuerbach, S; Lenhart, M; Link, J; Paetzel, C; Pfister, K; Schleicher, T; Stern, U, 2004) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 1.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| "Ticlopidine was significantly effective only at 100 mg/kg p." | 1.28 | Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. ( Hara, H; Kitajima, A; Shimada, H; Tamao, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (11.70) | 18.7374 |
| 1990's | 20 (21.28) | 18.2507 |
| 2000's | 44 (46.81) | 29.6817 |
| 2010's | 19 (20.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baudoin, Y | 1 |
| Guilhem, K | 1 |
| Meyrat, L | 1 |
| Thouard, H | 1 |
| Chen, YX | 1 |
| Wang, WD | 1 |
| Song, XJ | 1 |
| Gu, YQ | 1 |
| Tian, HY | 1 |
| Hu, HJ | 1 |
| Zhao, JC | 1 |
| Li, XQ | 1 |
| Liu, CW | 1 |
| Huebert, I | 1 |
| Heinicke, N | 1 |
| Kook, D | 1 |
| Boost, KA | 1 |
| Miller, CV | 1 |
| Mayer, WJ | 1 |
| Haritoglou, C | 1 |
| Kampik, A | 1 |
| Gandorfer, A | 1 |
| Hintschich, C | 1 |
| Wolf, A | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Hummel, T | 1 |
| Meves, SH | 1 |
| Rüdiger, K | 1 |
| Mügge, A | 1 |
| Mumme, A | 1 |
| Burkert, B | 1 |
| Mühlberger, D | 1 |
| Neubauer, H | 1 |
| Zuo, FT | 1 |
| Liu, H | 1 |
| Wu, HJ | 1 |
| Su, N | 1 |
| Liu, JQ | 1 |
| Dong, AQ | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Tacke, J | 1 |
| Lindhoff-Last, E | 4 |
| Linnemann, B | 3 |
| Schwonberg, J | 1 |
| Rechner, AR | 1 |
| Mani, H | 3 |
| Létienne, R | 1 |
| Leparq-Panissié, A | 1 |
| Calmettes, Y | 1 |
| Nadal-Wollbold, F | 1 |
| Perez, M | 1 |
| Le Grand, B | 1 |
| Liu, L | 1 |
| Zeng, F | 1 |
| Zeng, X | 1 |
| Xue, Q | 1 |
| Nie, S | 1 |
| Kang, C | 1 |
| Wu, J | 1 |
| Kang, Q | 1 |
| Wang, X | 3 |
| Liu, X | 1 |
| Li, T | 1 |
| Chen, J | 1 |
| Li, Q | 1 |
| Xu, R | 1 |
| Yang, X | 1 |
| Kang, H | 1 |
| Jiang, F | 1 |
| Li, Z | 1 |
| Zhang, L | 1 |
| Long, Y | 1 |
| Mehmeti, N | 1 |
| Budak, K | 1 |
| Meier, T | 1 |
| Schneider, JR | 1 |
| Verta, MJ | 1 |
| Alonzo, MJ | 1 |
| Hahn, D | 1 |
| Patel, NH | 1 |
| Kim, S | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 1 |
| Wiesemann, S | 1 |
| Passlick, B | 1 |
| Thalhammer, A | 1 |
| Wolf, Z | 1 |
| Tirneci, V | 1 |
| Vogl, TJ | 1 |
| Edelgard Lindhoff-Last, A | 1 |
| Cooley, BC | 1 |
| Meyer, S | 1 |
| Liang, GZ | 1 |
| Zhang, FX | 1 |
| Luo, XY | 1 |
| Zhang, CM | 1 |
| Hu, L | 1 |
| Feng, YP | 1 |
| Niu, LY | 1 |
| Zhang, H | 1 |
| Ma, BB | 1 |
| Qi, HS | 1 |
| Guo, MM | 1 |
| Long, YY | 1 |
| Li, HL | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Turpie, AG | 1 |
| Hiller, E | 1 |
| Pasqualini, L | 1 |
| Pirro, M | 1 |
| Lombardini, R | 1 |
| Ciuffetti, G | 1 |
| Dragani, P | 1 |
| Mannarino, E | 1 |
| Ziegler, S | 1 |
| Maca, T | 1 |
| Alt, E | 1 |
| Speiser, W | 1 |
| Schneider, B | 1 |
| Minar, E | 2 |
| Wohlgemuth, WA | 1 |
| Bohndorf, K | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Strecker, EP | 1 |
| Boos, IB | 1 |
| Göttmann, D | 1 |
| Vetter, S | 1 |
| Yilmaz, S | 1 |
| Sindel, T | 1 |
| Yegin, A | 1 |
| Lüleci, E | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 1 |
| Schmieder, FA | 1 |
| Throm, RC | 1 |
| Gaughan, JP | 1 |
| Rao, AK | 1 |
| Bal dit Sollier, C | 1 |
| Mahé, I | 1 |
| Berge, N | 1 |
| Simoneau, G | 1 |
| Bergmann, JF | 1 |
| Drouet, L | 1 |
| Aronow, WS | 1 |
| Clagett, GP | 2 |
| Sobel, M | 1 |
| Jackson, MR | 2 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 2 |
| Conforto, AB | 1 |
| Puglia, P | 1 |
| Yamamoto, FI | 1 |
| Scaff, M | 1 |
| Diehm, C | 1 |
| Lawall, H | 1 |
| Huber, R | 1 |
| Füessl, HS | 1 |
| Butz, B | 1 |
| Paetzel, C | 1 |
| Stern, U | 1 |
| Schleicher, T | 1 |
| Pfister, K | 1 |
| Link, J | 1 |
| Feuerbach, S | 1 |
| Lenhart, M | 1 |
| Xu, L | 1 |
| Eryonucu, B | 1 |
| Tuncer, M | 1 |
| Erkoc, R | 1 |
| Durand-Zaleski, I | 1 |
| Bertrand, M | 2 |
| Weintraub, W | 1 |
| Jönsson, B | 1 |
| Baumgartner, I | 1 |
| Klinkhardt, U | 1 |
| Harder, S | 1 |
| Hoefer, IE | 1 |
| Grundmann, S | 1 |
| Schirmer, S | 1 |
| van Royen, N | 1 |
| Meder, B | 1 |
| Bode, C | 1 |
| Piek, JJ | 1 |
| Buschmann, IR | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Heiss, JM | 1 |
| Kirichenko, AA | 1 |
| Wong, S | 1 |
| Morel-Kopp, MC | 1 |
| Chen, Q | 1 |
| Appleberg, M | 1 |
| Ward, CM | 1 |
| Lewis, DR | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Luxembourg, B | 2 |
| Kirchmayr, K | 1 |
| Collins, P | 1 |
| Ford, I | 1 |
| Greaves, M | 1 |
| Macaulay, E | 1 |
| Brittenden, J | 1 |
| Singer, E | 1 |
| Imfeld, S | 1 |
| Hoffmann, U | 1 |
| Buschmann, I | 1 |
| Labs, KH | 1 |
| Jaeger, KA | 1 |
| Toennes, SW | 1 |
| Strubel, G | 1 |
| Klaeffling, C | 1 |
| Daemgen-von Brevern, G | 1 |
| Geisen, C | 1 |
| Mortensen, J | 1 |
| Poulsen, TS | 1 |
| Refsgaard, J | 1 |
| Kristensen, SD | 1 |
| Landolfi, R | 1 |
| Di Gennaro, L | 1 |
| Stiegler, H | 2 |
| Hess, H | 1 |
| Mietaschk, A | 1 |
| Trampisch, HJ | 1 |
| Ingrisch, H | 1 |
| Katsumura, T | 2 |
| Day, HJ | 1 |
| Goebel, N | 1 |
| Pfluger, N | 1 |
| Speiser, K | 1 |
| Turina, M | 1 |
| Rothlin, M | 1 |
| Mishima, Y | 1 |
| Kamiya, K | 1 |
| Sakaguchi, S | 1 |
| Tanabe, T | 1 |
| Sakuma, A | 1 |
| Klingemann, HG | 1 |
| Egbring, R | 1 |
| Fitzgerald, GA | 1 |
| Meagher, EA | 1 |
| Shirakura, S | 1 |
| Higo, K | 1 |
| Takeda, M | 1 |
| Karasawa, A | 1 |
| van Gijn, J | 1 |
| Algra, A | 1 |
| Andreozzi, GM | 1 |
| Signorelli, SS | 1 |
| Cacciaguerra, G | 1 |
| Di Pino, L | 1 |
| Martini, R | 1 |
| Monaco, S | 1 |
| Buttò, G | 1 |
| Sardina, M | 1 |
| Castillo, V | 1 |
| Bogousslavsky, J | 1 |
| Vuadens, P | 1 |
| Ishida, H | 2 |
| Nakayasu, H | 2 |
| Nukaya, H | 2 |
| Tsuji, K | 2 |
| Bertrand, ME | 1 |
| Legrand, V | 1 |
| Boland, J | 1 |
| Fleck, E | 1 |
| Bonnier, J | 1 |
| Emmanuelson, H | 1 |
| Vrolix, M | 1 |
| Missault, L | 1 |
| Chierchia, S | 1 |
| Casaccia, M | 1 |
| Niccoli, L | 1 |
| Oto, A | 1 |
| White, C | 1 |
| Webb-Peploe, M | 1 |
| Van Belle, E | 1 |
| McFadden, EP | 1 |
| Hilleman, DE | 1 |
| Koskin, VM | 1 |
| Bogdanets, LI | 1 |
| Priollet, P | 1 |
| Forbes, CD | 1 |
| Lowe, GD | 1 |
| MacLaren, M | 1 |
| Shaw, BG | 1 |
| Dickinson, JP | 1 |
| Kieffer, G | 1 |
| Redlich, K | 1 |
| Parschalk, B | 1 |
| Ehringer, H | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| Kaufman, JS | 1 |
| Fiore, L | 1 |
| Hasbargen, JA | 1 |
| O'Connor, TZ | 1 |
| Perdriset, G | 1 |
| Gusak, VK | 1 |
| Shtutin, AA | 1 |
| Rodin, IuV | 1 |
| Il'iushchenko, SV | 1 |
| Iurchuk, AIu | 1 |
| Haldemann, R | 1 |
| Lüscher, TF | 1 |
| Szucs, TD | 1 |
| Sugio, Y | 1 |
| Okamura, T | 1 |
| Shimoda, K | 1 |
| Matsumoto, M | 1 |
| Yagi, H | 1 |
| Ishizashi, H | 1 |
| Niho, Y | 1 |
| Inaba, S | 1 |
| Fujimura, Y | 1 |
| Bartorelli, AL | 1 |
| Trabattoni, D | 1 |
| Montorsi, P | 1 |
| Fabbiocchi, F | 1 |
| Galli, S | 1 |
| Ravagnani, P | 1 |
| Grancini, L | 1 |
| Cozzi, S | 1 |
| Loaldi, A | 1 |
| Blanchard, JF | 1 |
| Carreras, LO | 1 |
| Coccheri, S | 1 |
| Palareti, G | 1 |
| Fortunato, G | 1 |
| Hara, H | 1 |
| Shimada, H | 1 |
| Kitajima, A | 1 |
| Tamao, Y | 1 |
| Arcan, JC | 1 |
| Panak, E | 1 |
| Gemelli, A | 1 |
| Leone, G | 1 |
| Berni, A | 1 |
| Pacelli, M | 1 |
| Harker, LA | 1 |
| Arpaia, MR | 1 |
| Leonardo, G | 1 |
| del Guercio, R | 1 |
| Di Perri, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
19 reviews available for ticlopidine and Arterial Occlusive Diseases
| Article | Year |
|---|---|
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
Revaluation of clopidogrel: let the data speak for themselves.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; | 2010 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
[Endovascular brachytherapy to prevent restenosis after angioplasty].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Brachyth | 2003 |
Antiplatelet therapy in peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Humans; Peripheral Vascular Disease | 2004 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Multicenter Studie | 2004 |
The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Benchmarking; Clopidogrel; Dru | 2004 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
[Mechanism of action and clinical use of ticlopidine].
Topics: Arterial Occlusive Diseases; Brain Ischemia; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Myo | 2006 |
Overview: clinical experiences with ticlopidine.
Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinica | 1984 |
Antiplatelet drugs.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Dipyridamole; Humans; Integrins; Platelet Aggregation | 1994 |
[Preventive treatment of cerebrovascular accidents of arterial origin].
Topics: Adult; Aged; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials | 1996 |
Management of peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopid | 1998 |
[Ticlid: clinical effectiveness and significance in combined conservative treatment of chronic obliterating diseases of lower limb arteries].
Topics: Arterial Occlusive Diseases; Chronic Disease; Humans; Leg; Platelet Aggregation Inhibitors; Safety; | 1998 |
Antithrombotic therapy in peripheral arterial occlusive disease.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C | 1998 |
[Arteriopathy of the lower limbs: toward a global medical care].
Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Cl | 1999 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
21 trials available for ticlopidine and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Kaplan-Meier Es | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
[Prevalence of acetylsalicylic acid (ASA) - low response in vascular surgery].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Stenosi | 2016 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The | 2017 |
Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Catheterization, Per | 2010 |
[A prospective randomized control clinical trial about clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after femoral-popliteal artery angioplasty].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Clopidogrel; Fema | 2012 |
A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.
Topics: Adult; Arterial Occlusive Diseases; Blood Platelets; Blood Viscosity; Cell Adhesion; Clopidogrel; Do | 2002 |
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co | 2003 |
Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cardiovascular Disea | 2006 |
Aspirin in peripheral arterial disease: breakthrough or pitfall?
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Collateral Circulation; Combined Modality Therapy | 2006 |
[Effect of ticlopidine on peripheral obliterating arteriopathy].
Topics: Angiography; Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Blind Met | 1984 |
Therapeutic effect of ticlopidine for ischemic leg ulcers.
Topics: Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Humans; Ischemia; Leg | 1984 |
Overview: clinical experiences with ticlopidine.
Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinica | 1984 |
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1982 |
Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
Topics: Arterial Occlusive Diseases; Blood Gas Monitoring, Transcutaneous; Exercise Test; Female; Fibrinolyt | 1993 |
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease; | 1998 |
Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Arterial Occlusive Diseases; Atenolol; Calcium Channel Blockers; | 1999 |
[Application of preparation endotelon in complex treatment of chronic arterial insufficiency of lower extremities].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arterial Occlusive Diseases; Aspirin; Biflavo | 2000 |
Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Carbon; Coa | 2002 |
A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group.
Topics: Adult; Aged; Argentina; Arterial Occlusive Diseases; Double-Blind Method; Female; Follow-Up Studies; | 1992 |
Ticlopidine in the treatment of peripheral occlusive arterial disease.
Topics: Arterial Occlusive Diseases; Blood Flow Velocity; Clinical Trials as Topic; Exercise Test; Humans; I | 1989 |
55 other studies available for ticlopidine and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Images of an occlusive arterial disease of lower extremity due to chronic intoxication by ergot alkaloid.
Topics: Arterial Occlusive Diseases; Clopidogrel; Drug Substitution; Female; Humans; Lower Extremity; Methys | 2014 |
Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia.
Topics: Aged; Anesthesia, Local; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiac Surgical Proc | 2015 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
Topics: Animals; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Clopido | 2010 |
[Diagnosis of peripheral arterial occlusive disease].
Topics: Algorithms; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Blood Pressure Determination | 2010 |
Results with Viabahn-assisted subintimal recanalization for TASC C and TASC D superficial femoral artery occlusive disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arterial Occlus | 2011 |
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com | 2012 |
Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Bicycling; Clopidogrel; Constriction, Pathologic; Dr | 2012 |
Collagen-induced thrombosis in murine arteries and veins.
Topics: Animals; Arterial Occlusive Diseases; Blood Coagulation; Blood Platelets; Carotid Arteries; Clopidog | 2013 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
[Long-term anticoagulation after bypass operation].
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Humans; Long-Term Care; Platelet Aggregation Inhi | 2002 |
Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Blood Platelets; | 2002 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Anticoagula | 2004 |
Subintimal angioplasty of long superficial femoral artery occlusions.
Topics: Angioplasty; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Female; Femoral Artery; Fibrinolytic | 2003 |
Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment: kinetics of the effect and influence of single and double loading-dose regimens.
Topics: Adult; Arterial Occlusive Diseases; Clopidogrel; Confidence Intervals; Drug Administration Schedule; | 2003 |
[Even when walking yet does not cause any pain, peripheral arterial occlusive disease costs life years].
Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Humans; | 2003 |
Progressive cervicocranial arteriopathy with dilatations and stenoses: case report.
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Basilar Artery; Carotid Artery Diseases; Carotid Artery | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art | 2004 |
[Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!].
Topics: Arterial Occlusive Diseases; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Emboli | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiography; Anticoagulants; Arterial Occlusive Disea | 2004 |
An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research.
Topics: Animals; Arterial Occlusive Diseases; Carotid Artery Diseases; Chlorides; Clopidogrel; Disease Model | 2005 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedul | 2004 |
[In diabetes and peripheral arterial occlusive disease: long-term treatment with clopidogrel].
Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Humans; L | 2005 |
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
Topics: Adenosine Diphosphate; Adult; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Clopidogrel; Fl | 2005 |
Aspirin, but not clopidogrel, reduces collateral conductance in a rabbit model of femoral artery occlusion.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Disease Models, Animal; Electrophysiolog | 2005 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
[Emergency measures in acute arterial occlusion. Why there are still colleagues who do it incorrectly?].
Topics: Acute Disease; Angiography; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Embolism; Emergencies | 2006 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
Response to aspirin and clopidogrel monitored with different platelet function methods.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Automation; Blood Platelets; Clopidogrel; Female; Humans | 2006 |
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation; | 2006 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co | 2007 |
Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders?
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Automation; Blood Platelets; Clopidogrel; Female; Humans | 2007 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
[Changes in the unmodified vessels after aortocoronary bypass surgery].
Topics: Angina Pectoris; Anticoagulants; Arterial Occlusive Diseases; Coronary Artery Bypass; Coronary Disea | 1983 |
[Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
Topics: Adult; Arterial Occlusive Diseases; Blood Coagulation Factors; Double-Blind Method; Female; Humans; | 1982 |
Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Benzimidazoles; Benzoxepins; Blood Coagulation; Blood | 1994 |
Ticlopidine, trials, and torture.
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebrovascular Disorders; Clinical Trials as | 1994 |
[Oral anticoagulation in activated protein C resistance?].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Drug Resistance; Humans; Male; Middle Aged; Ph | 1996 |
Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizoprionodon acutus. II. Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model.
Topics: Animals; Antithrombins; Arginine; Arterial Occlusive Diseases; Blood Coagulation; Cholestanols; Elas | 1998 |
Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizoprionodon acutus. III. Protective effect of scymnol against vascular endothelial cell damage in a rat peripheral arterial occlusion model.
Topics: Alanine Transaminase; Animals; Antithrombin III; Arginine; Arterial Occlusive Diseases; Aspartate Am | 1999 |
Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C.
Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Female; Hepatitis C, Chronic; Humans; Leukemia, Lymp | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Chronic Disease; Clopidogrel; Dose-Response Rela | 2000 |
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Clopido | 2001 |
Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Arterial Occlusive Diseases; Autoantibodies; Humans; Immunog | 2001 |
Ticlopidine.
Topics: Arterial Occlusive Diseases; Humans; Ticlopidine | 1991 |
Prophylactic antiplatelet therapy in peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Arteries; Humans; Leg; Peripheral Vascular Diseases; Platelet Aggregati | 1991 |
Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease.
Topics: Animals; Arterial Occlusive Diseases; Carrageenan; Fibrinolytic Agents; Infarction; Lauric Acids; Ma | 1991 |
[Use of ticlopidine in a group of patients with obliterative arteriopathy of the lower extremities].
Topics: Arterial Occlusive Diseases; Drug Evaluation; Gait; Humans; Leg; Ticlopidine; Time Factors | 1987 |
[Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood].
Topics: Aged; Arterial Occlusive Diseases; Equipment and Supplies; Evaluation Studies as Topic; Female; Huma | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |